Role of ultra low dose CTKUB in follow-up of ureteric calculi not visible on plain X-ray

Background : The first case of COVID-19 in Indonesia was recorded in March 2020. Limitation of reverse-transcription polymerase chain reaction (RT-PCR) has put chest CT as an essential complementary tool in the diagnosis and follow up treatment for COVID-19. Literatures strongly suggested that High-Resolution Computed Tomography (HRCT) is essential in diagnosing typical symptoms of COVID-19 at the early phase of disease due to its superior sensitivity (97%) compared to chest x-ray (CXR).The two cases presented in this case study showed the crucial role of chest CT with HRCT to establish the working diagnosis and follow up COVID-19 patients as a complement to RT-PCR, currently deemed a gold standard.

Download Full-text

Descriptive study of chest x-ray examination in mandatory annual health examinations at the workplace in Japan

PLoS ONE ◽

10.1371/journal.pone.0262404 ◽

2022 ◽

Vol 17 (1) ◽

pp. e0262404

Author(s):

Yuya Watanabe ◽

Toru Nakagawa ◽

Kota Fukai ◽

Toru Honda ◽

Hiroyuki Furuya ◽

...

Keyword(s):

Computed Tomography ◽

Lung Cancer ◽

Detection Rate ◽

Low Dose ◽

Care Center ◽

Stage I ◽

X Ray ◽

Health Care Center ◽

Chest X Ray

The utility of chest x-ray examination (CXR) in mandatory annual health examinations for occupational health is debatable in Japan. This study aimed to provide basic data to consider future policies for mandatory annual health examinations in the workplace. A nationwide descriptive survey was performed to determine the rate of detection of tuberculosis, lung cancer, and other diseases through CXR in organizations associated with National Federation of Industrial Health Association. The rate of finding on CXR conducted during annual health examinations in FY2016 was evaluated. Data regarding diagnosis based on follow-up examination findings were obtained and compared with the national statistics. In addition, CXR findings were compared with the results of low-dose lung computed tomography performed at the Hitachi Health Care Center. From 121 surveyed institutions, 88 institutions with 8,669,403 workers were included. For all ages, 1.0% of examinees required follow-up examination. Among 4,764,985 workers with diagnosis data, the tuberculosis detection rate was 1.8–5.3 per 100,000 persons. For Lung cancer, 3,688,396 workers were surveyed, and 334 positive cases were detected. The lung cancer detection rate using CXR was 9.1–24.4 per 100,000 persons. From 164 cases with information regarding the clinical stage, 72 (43.9%) had Stage I lung cancer. From 40,045 workers who underwent low-dose computed tomography multiple times, 31 lung cancer cases, all with Stage I disease, were detected (detection rate: 77.4 per 100,000 persons). Our findings suggest that CXR plays a little role in the detection of active tuberculosis. With regard to LC screening, the detection rate of LC by CXR was lower, approximately 50%, than the expected rate (41.0 per 100,000 persons) of LC morbidity based on the age–sex distribution of this study population. However, the role of CXR for LC screening cannot be mentioned based on this result, because assessment of mortality reduction is essential to evaluate the role.

Download Full-text

The role of androgen ablation with low dose rate brachytherapy in the treatment of prostate cancer

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.14546 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 14546-14546

Author(s):

A. B. Jani ◽

A. Shoushtari ◽

J. Feinstein

Keyword(s):

Multivariate Analysis ◽

Prognostic Factors ◽

High Risk ◽

Dose Rate ◽

Low Dose ◽

Androgen Ablation ◽

Low Dose Rate ◽

Low Dose Rate Brachytherapy

14546 Background: We report a single-institution analysis of the role of androgen ablation (AA) with low-dose rate brachytherapy. Methods: A cohort of 189 consecutive patients (AA: n = 68, no-AA: n = 121) receiving brachytherapy (iodine-125: n = 125; palladium-109: n = 64) at our institution who had demographic (age), disease (T-stage [T1–70%, T2–28%, T3–2%], Gleason Score [median score 6], PSA [median-7.7 ng/mL]), and treatment (isotope, dosimetric endpoints, use of supplemental external beam radiotherapy [EBRT, administered as 45 Gy/1.8 Gy to the pelvis using 4-field technique with isocentric prescription]) information available, and a minimum of 2 years of follow-up available, constitute the analysis study group (median follow-up - 4.0 years). This cohort was divided into 2 major groups based on the use of AA (leuprolide 22.5 mg IM injection(s) 3–6 months [mean 4.0 months] prior to brachytherapy). Using 2 successive PSA rises > 1 ng/mL as the failure definition, biochemical failure-free survival (BFFS) curves were constructed and compared using the logrank test; additionally, multivariate analysis of all major patient and treatment factors was performed using the Cox proportional hazards model. These analyses were done for the whole cohort as well as for subgroups defined by the use of EBRT and for subgroups of patients with low-, intermediate-, and high-risk prognostic factors (defined as the basis of 0, 1, or ≥ 2 prognostic factors [PSA > 10 ng/mL, Gleason score > 6, T-stage > T2a], repectively). Results: The 4-year BFFS in the AA vs no-AA groups was 76 vs 70% (p = 0.230) for the whole cohort, 75 vs 62% (p = 0.182) for EBRT patients, and 75 vs 82% (p = 0.764) for no-EBRT patients. For the whole cohort, the use of EBRT was the only factor reaching significance on multivariate analysis (p = 0.040). When analyzing the EBRT and no-EBRT subgroups separately, no factor, including AA, reached significance on multivariate analysis. 4Y-BFFS of the AA vs no-AA subgroups were 82 vs 76% (p = 0.236) for the low-risk, 76 vs 70% (p = 0.437) for the intermediate-risk, and 75 vs 70% (p = 0.185) for the high-risk subgroup. Conclusions: In our study, short-course AA conferred no significant biochemical control advantage when added to low-dose rate brachytherapy overall or for any subgroup based on prognostic risk. No significant financial relationships to disclose.

Download Full-text

Lenalidomide and Dexamethasone Alone Is Equivalent To Lenalidomide and Dexamethasone With Autologous Stem Cell Transplant In Newly Diagnosed Multiple Myeloma: Interim Study Results Of a Randomized Trial

Blood ◽

10.1182/blood.v122.21.3180.3180 ◽

2013 ◽

Vol 122 (21) ◽

pp. 3180-3180 ◽

Cited By ~ 1

Author(s):

Jordan M. Schecter ◽

Kristen Kipps ◽

Amy O'Sullivan ◽

Kent A. Griffith ◽

Daniel Normolle ◽

...

Keyword(s):

Multiple Myeloma ◽

Stem Cell ◽

Interim Analysis ◽

Research Funding ◽

Low Dose ◽

Secondary Malignancy ◽

Similar Response ◽

Newly Diagnosed

Abstract The current standard of care for patients with newly diagnosed multiple myeloma (MM) aged less than 65 years is high-dose chemotherapy combined with autologous stem cell transplantation (ASCT) based on improved progression free survival (PFS) and overall survival (OS) compared with conventional chemotherapy. The introduction of novel agents, for example lenalidomide and bortezomib over the last decade, has substantially improved MM outcomes providing similar response rates to ASCT. As a consequence, the role of upfront ASCT has become more controversial. Therefore, this randomized clinical trial aims to determine the role of upfront ASCT in patients with newly diagnosed MM patients receiving lenalidomide and low-dose dexamethasone as induction therapy. Patients enrolled into the study were aged ≥18 years with newly diagnosed MM, transplant eligible, and meeting CRAB criteria. Patients were randomized to receive 4 cycles of lenalidomide (25 mg days 1–21) plus low-dose dexamethasone (40 mg days 1, 8, 15, 22) followed by ASCT conditioned with 200 mg/m2 melphalan (Arm A; LD+ASCT) or 8 cycles of lenalidomide plus low-dose dexamethasone (Arm B; LD alone). Both groups received lenalidomide maintenance therapy 10-15 mg for up to 2 years. Patients in both treatment arms received stem cell collection after 4 cycles of lenalidomide plus dexamethasone if at least a partial response was achieved. Patients with stable disease or progressive disease (PD) went off study. The primary objective was to compare the best response between patients treated with lenalidomide plus dexamethasone followed by ASCT and patients treated with lenalidomide plus dexamethasone alone. Secondary objectives were to compare the duration of response (DOR), PFS, and OS between the two treatment arms and to evaluate the secondary malignancies in both arms. Fifty patients with newly diagnosed MM were randomized between February 2008 and May 2013, and 47 patients were eligible for evaluation in this interim analysis; 25 patients randomized to Arm A (LD+ASCT) and 22 patients randomized to Arm B (LD alone). Overall, patients had a median age of 61.6 years (range 48–75), 60% were male, 34% ISS Stage I, 49% ISS Stage II, 17% ISS Stage III. The data were analyzed according to the IMWG response criteria (Blood. 2011 May 5;117(18):4691-5). In an intention-to-treat analysis, there was a trend towards improved overall response rate (ORR) in patients receiving LD+ASCT (96%) compared with patients receiving LD alone (77%; p=0.08) (Table 1). After a median follow-up of 36.8 months (range 1.1–62.7), the median DOR was 13.9 months (95% confidence interval [CI] 4.0–34.1) in the LD+ASCT group compared with 21.2 months (95% CI 11.0–22.9) in the LD group. Overall, 18 patients have PD (10 patients in the LD+ASCT arm and 8 patients in LD arm), and 8 patients have died (4 patents in the LD+ASCT arm and 4 patients in the LD arm). Median PFS for LD+ASCT versus LD was 17.0 months (95% CI 15.5–not estimable) versus 25.2 months (95% CI 9.0–not estimable; p=0.94). Median OS for LD+ASCT versus LD was 57.6 months (95% CI 48.0–not estimable) versus not reached (p=0.94). Two patients in the LD alone arm developed a secondary malignancy, including 1 patient with myelodysplastic syndrome (MDS) 13 months after the start of therapy. This interim analysis of an ongoing randomized clinical study comparing lenalidomide plus low-dose dexamethasone induction with and without upfront ASCT in patients with newly diagnosed MM suggests that addition of ASCT resulted in a trend towards improved ORR. This did not result in a significant difference in terms of PFS or OS between the two treatment arms. In contrast there was a trend of better DOR in the LD alone arm. The data show that LD alone can achieve similar results as LD+ASCT, however careful interpretation is required due to the low patient number and relatively short follow-up. The incidence of secondary malignancy was low, including the development of 1 MDS. Disclosures: Schecter: Celgene: Honoraria, Speakers Bureau. Mapara:Celgene: Research Funding, RO1 Other. Lentzsch:Celgene: Research Funding.

Download Full-text

Development of Central Serous Chorioretinopathy following Chalazion Removal with Intralesional Triamcinolone Injection: A Case Report

Case Reports in Ophthalmology ◽

10.1159/000492714 ◽

2018 ◽

Vol 9 (3) ◽

pp. 416-420 ◽

Cited By ~ 3

Author(s):

Luca Rosignoli ◽

Stephen Myles Potter ◽

Andres Gonzalez ◽

Sarina Amin ◽

Syed G. Khurshid

Keyword(s):

Visual Acuity ◽

Central Serous Chorioretinopathy ◽

Low Dose ◽

Subretinal Fluid ◽

Intralesional Injection ◽

Short Term ◽

Corticosteroid Administration ◽

Triamcinolone Injection

We report a case of central serous chorioretinopathy (CSC) that developed 1 month after an intralesional injection of triamcinolone acetonide that was administered during removal of a chalazion. The subretinal fluid and ipsilateral visual acuity (VA) worsened with initial observation. The edema resolved with verteporfin photodynamic therapy (PDT) 1 month after diagnosis, but VA did not improve during short-term follow-up. We conclude that CSC can occur as a complication of low-dose intrapalpebral corticosteroid administration and provide another example of the therapeutic role of PDT in the management of this disease.

Download Full-text

Role of low dose CT angiography in the follow-up after endovascular aneurysm repair of abdominal aorta

Acta Radiologica ◽

10.1177/0284185114560210 ◽

2014 ◽

Vol 56 (12) ◽

pp. 1471-1478 ◽

Cited By ~ 2

Author(s):

Monica Macchi ◽

Chiara Floridi ◽

Sabina Strocchi ◽

Federico Fontana ◽

Monica Mangini ◽

...

Keyword(s):

Ct Angiography ◽

Abdominal Aorta ◽

Low Dose ◽

Endovascular Aneurysm Repair ◽

Low Dose Ct ◽

Aneurysm Repair

Download Full-text

Consensus Guidelines of Russian Society of Radiology (RSR) and Russian Association of Specialists in Ultrasound Diagnostics in Medicine (RASUDM) «Role of Imaging (X-ray, CT and US) in Diagnosis of COVID-19 Pneumonia» (version 2)

Journal of radiology and nuclear medicine ◽

10.20862/0042-4676-2020-101-2-72-89 ◽

2020 ◽

Vol 101 (2) ◽

pp. 72-89

Author(s):

V. E. Sinitsyn ◽

I. E. Tyurin ◽

V. V. Mitkov

Keyword(s):

Intensive Care ◽

Lung Tissue ◽

Russian Society ◽

Lung Pathology ◽

Consensus Guidelines ◽

X Ray ◽

Ultrasound Diagnostics ◽

Russian Association

The paper presents Consensus Guidelines of Russian Society of Radiology (RSR) and Russian Association of Specialists in Ultrasound Diagnostics in Medicine (RASUDM) «Role of imaging (X-ray, CT and US) in diagnosis of COVID-19 pneumonia» (version 2) of the Russian Society of Radiology and the Russian Association of Specialists in Ultrasound Diagnostics in Medicine.The guidelines list radiological techniques for lung diseases, which are used in coronavirus COVID-19 infection (chest X-ray, lung computed tomography (CT), and lung ultrasound (US), diagnostic algorithm, and follow-up study. The guidelines propose the models of the work of radiological rooms/departments of a healthcare facility, the procedure for conducting an examination, and recommendations for providing a description and assessing changes in the lung and chest in existing/suspected COVID-19-related pneumonia and present the schemes of X-ray and CT protocols at the initial examination and assessment of the changes.Chest X-ray has a low sensitivity for detecting initial changes in the first days of the disease and is not recommended for early diagnosis. Mobile radiography is an important tool for diagnosis of lung pathology in the intensive care units.CT is the most sensitive technique in detecting lung changes characteristic of COVID-19-related pneumonia. It is advisable to use CT for the initial evaluation of thoracic organs in patients with severe and progressive forms of the disease, as well as for the differential diagnosis and follow up.Lung US in patients with suspected/known COVID-19-related pneumonia is an additional imaging method that does not replace or exclude X-ray and CT. If the correct procedure is followed, correct indications are selected, and trained medical personnel is available, this study is highly sensitive in detecting interstitial changes and consolidations in lung tissue, but only in their subpleural location. The US data do not always allow definite determination of the reasons for the occurrence and/or actual extent of lung tissue changes.Standard reporting guidelines (CT, X-ray) about the possibility of COVID-19 pneumonia and its severity should be used.The follow up using CT, X-ray, or US depends on the clinical indications that necessitate dynamic assessment. The recommended frequency of repeat CT and X-ray in patients having no substantial changes in their clinical condition outside the intensive care units is not more than once every 5-7 days. An objective assessment of the time course of changes is possible only when comparing the data of the same type of study.

Download Full-text

Late-stage Use of Low-dose Corticosteroids Aid Recovery of Severe H1N1 Viral Pneumonia

Infection International ◽

10.1515/ii-2017-0054 ◽

2013 ◽

Vol 2 (3) ◽

pp. 132-136 ◽

Cited By ~ 1

Author(s):

Bin Cao ◽

Li Gu ◽

Xiao-min Yu ◽

Yu-Dong Yin ◽

Chen Ma ◽

...

Keyword(s):

Influenza A ◽

Low Dose ◽

H1n1 Pandemic ◽

Organizing Pneumonia ◽

X Ray ◽

Influenza A H1n1 ◽

Chest X Ray ◽

Bacteria And Fungi ◽

Lung Infiltrates

Abstract The role of corticosteroids in the management of severely ill patients with influenza A (H1N1) viral infection is unclear and controversial. Two critically ill cases with influenza A (H1N1) infections complicated with organizing pneumonia (OP) in 2011 successfully treated with low dose corticosteroids were reported here. After initial clinical improvement, the condition of both patients aggravated 20-23 days after the onset of illness. Chest X-ray and computed tomographies (CT) showed an increment of lung infiltrates. Cultures of blood, pleural fluid and transbronchial aspirate were negative for bacteria and fungi. Organizing pneumonia was diagnosed clinically and both patients were successfully treated with low-dose corticosteroids. Low-dose corticosteroids initiated during convalescence may be beneficial for severe swine-origin influenza A H1N1 pandemic 2009 virus (S-OIV) infections.

Download Full-text